Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...
Mitochondrial DNA (mtDNA) exhibits a degree of resistance to mutagenesis under genotoxic stress, and this study on the mitochondrial Transcription Factor A (TFAM) presents valuable data concerning the ...
Artios Pharma, a Babraham-based biopharma company realising the therapeutic power of targeting the DNA damage response in ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...
Funding advances Phase 2 expansion cohorts in pancreatic and colorectal cancer in ATM-negative patients for Artios’ potential ...
Artios Pharma collected $115 million from an oversubscribed series D that will support its growing ambitions for its pipeline ...
Onlymyhealth on MSN
Google's Doodle Decodes DNA: All the Facts and Science It Explains
On November 13, 2025, Google users in India were greeted with a smart twist when Google’s iconic logo had transformed into a ...
A newly developed mouse model enables real-time visualization of RNA Polymerase II (RNAP2) during DNA transcription, as ...
Maximize capping efficiency and minimize double-stranded RNA ("dsRNA") in the manufacturing of self-amplifying mRNA SAN DIEGO ...
Artios Pharma is working on a pipeline of oncology assets, led by alnodesertib, currently being tested for second-line ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) Q3 2025 Earnings Call Transcript November 12, 2025 Acurx Pharmaceuticals, Inc.
BOSTON, Nov. 10, 2025 /PRNewswire/ -- Fapon, a globally leading life sciences organization, will exhibit at the AMP 2025 Annual Meeting & Expo during November 11-15 in Boston, presenting its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback